Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across Retatrutide · BPC-157 · MOTS-c

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

Retatrutide

Grade AMetabolic

Overview

Evidence grade: Grade A
Category: Metabolic
Primary focus: Triple GIP/GLP-1/glucagon agonist
Summary: Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

Mechanism

Mechanism of action: First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer: Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~6 days (supports once-weekly dosing)
PK notes: Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

Administration

Typical dose: Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency: Once weekly
Cycle length: Ongoing; weight regain occurs on cessation
Timing: Same day each week; any time of day
Protocol steps: Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly.
Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible.
Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: ~24% mean weight loss at 48 weeks (Phase II)
Marked improvements in HbA1c, blood pressure, ApoB and liver fat
Convenient once-weekly dosing
Likely best-in-class cardiometabolic profile
Common stacks: Creatine monohydrate, Whey protein, Vitamin D3 + K2

Risks

Side effects: Nausea, vomiting, diarrhea (especially during titration)
Injection site reactions
Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting
Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications: Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia type 2
Pregnancy and lactation
Prior severe reaction to GLP-1 agonists
Interactions: Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required.
Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status: Investigational; not yet FDA-approved. Currently available only via clinical trials.

BPC-157

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Tissue repair, gut integrity
Summary: Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Mechanism

Mechanism of action: Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or oral (gut-localized)
Half-life: ~4 hours (subcutaneous)
PK notes: BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Administration

Typical dose: 250–500 mcg
Frequency: 1–2× daily
Cycle length: 4–6 weeks on, 4 weeks off
Timing: Near site of injury or AM/PM fasted
Protocol steps: Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily.
Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible.
Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue recovery in preclinical models
Gut barrier integrity and ulcer protection
Potential nervous system neuroprotection
Common stacks: TB-500, Collagen peptides, Vitamin C

Risks

Side effects: Generally well tolerated in animal studies
Injection site irritation
Long-term human safety unknown
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical synergy via NO modulation — monitor.
VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status: Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

MOTS-c

Grade BMitochondrial

Overview

Evidence grade: Grade B
Category: Mitochondrial
Primary focus: Mitochondrial signaling
Summary: Promising mitokine with metabolic and exercise-mimetic effects in rodents. Early human pharmacokinetic data is emerging.

Mechanism

Mechanism of action: Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous
Half-life: ~2 hours
PK notes: MOTS-c is administered subcutaneous with an approximate systemic half-life of ~2 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2–3× weekly) is designed to match receptor kinetics rather than plasma exposure. Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.

Administration

Typical dose: 5–10 mg
Frequency: 2–3× weekly
Cycle length: 8–12 weeks
Timing: Pre-training mornings
Protocol steps: Route: Subcutaneous. Typical starting dose 5–10 mg, 2–3× weekly.
Timing: Pre-training mornings — keep it the same each dosing day to make effects legible.
Cycle length: 8–12 weeks. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Improved glucose disposal in preclinical models
Enhanced exercise capacity
Mitochondrial biogenesis signaling
Common stacks: NMN, Urolithin A, Zone 2 training

Risks

Side effects: Mild flushing
Transient fatigue
Injection site reaction
Contraindications: Active malignancy
Pregnancy
Interactions: Metformin — Both activate AMPK — stacking effect unclear.
SGLT2 inhibitors — Potential additive glucose-lowering.
Legal status: Research chemical. Not approved for therapeutic use in humans.

Attribute	Retatrutide Grade AMetabolic	BPC-157 Grade BRegenerative	MOTS-c Grade BMitochondrial
Overview
Evidence grade	Grade A	Grade B	Grade B
Category	Metabolic	Regenerative	Mitochondrial
Primary focus	Triple GIP/GLP-1/glucagon agonist	Tissue repair, gut integrity	Mitochondrial signaling
Summary	Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.	Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.	Promising mitokine with metabolic and exercise-mimetic effects in rodents. Early human pharmacokinetic data is emerging.
Mechanism
Mechanism of action	First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.	Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.	Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.
Evidence explainer	Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.
Pharmacokinetics
Route	Subcutaneous injection	Subcutaneous or oral (gut-localized)	Subcutaneous
Half-life	~6 days (supports once-weekly dosing)	~4 hours (subcutaneous)	~2 hours
PK notes	Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.	BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.	MOTS-c is administered subcutaneous with an approximate systemic half-life of ~2 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2–3× weekly) is designed to match receptor kinetics rather than plasma exposure. Mitochondrial-derived peptide encoded within the 12S rRNA. Activates AMPK, improves insulin sensitivity, and regulates nuclear gene expression in response to metabolic stress.
Administration
Typical dose	Titrated 2 mg → 4 mg → 8 mg → 12 mg	250–500 mcg	5–10 mg
Frequency	Once weekly	1–2× daily	2–3× weekly
Cycle length	Ongoing; weight regain occurs on cessation	4–6 weeks on, 4 weeks off	8–12 weeks
Timing	Same day each week; any time of day	Near site of injury or AM/PM fasted	Pre-training mornings
Protocol steps	Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly. Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible. Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily. Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible. Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous. Typical starting dose 5–10 mg, 2–3× weekly. Timing: Pre-training mornings — keep it the same each dosing day to make effects legible. Cycle length: 8–12 weeks. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	~24% mean weight loss at 48 weeks (Phase II) Marked improvements in HbA1c, blood pressure, ApoB and liver fat Convenient once-weekly dosing Likely best-in-class cardiometabolic profile	Accelerated soft-tissue recovery in preclinical models Gut barrier integrity and ulcer protection Potential nervous system neuroprotection	Improved glucose disposal in preclinical models Enhanced exercise capacity Mitochondrial biogenesis signaling
Common stacks	Creatine monohydrate, Whey protein, Vitamin D3 + K2	TB-500, Collagen peptides, Vitamin C	NMN, Urolithin A, Zone 2 training
Risks
Side effects	Nausea, vomiting, diarrhea (especially during titration) Injection site reactions Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting Theoretical pancreatitis and gallbladder risk (class effect)	Generally well tolerated in animal studies Injection site irritation Long-term human safety unknown	Mild flushing Transient fatigue Injection site reaction
Contraindications	Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia type 2 Pregnancy and lactation Prior severe reaction to GLP-1 agonists	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation	Active malignancy Pregnancy
Interactions	Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required. Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.	Anticoagulants — Theoretical synergy via NO modulation — monitor. VEGF inhibitors — Mechanistic opposition; avoid combination.	Metformin — Both activate AMPK — stacking effect unclear. SGLT2 inhibitors — Potential additive glucose-lowering.
Legal status	Investigational; not yet FDA-approved. Currently available only via clinical trials.	Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.	Research chemical. Not approved for therapeutic use in humans.

← Back to all peptides